Top Markets
#1 Cysic Cysic +7.96%
#2 Palladium Network Palladium Network +6.82%
#3 Pieverse Pieverse +3.88%
#4 Akedo Akedo +2.15%
#5 Bless Bless +1.27%
#6 aPriori aPriori +1.17%
#7 Prom Prom +1.16%
#8 Zest Protocol Zest Protocol +1.01%
#9 Test Test +0.95%
#10 Open Campus Open Campus +0.84%
Coin of the day
Cysic Cysic
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Rang in Aktien #40469
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Aktienkurs
$0.00204105
Zuletzt synchronisiert: 2026-08-13
Marktkapitalisierung
$138.92K
Veränderung (1 Tag)
5.63%
Veränderung (1 Jahr)
-51.33%
Land
GB
Handel Solvonis Therapeutics plc (SVNS)

Kategorie

Industrials
Gewinn für Solvonis Therapeutics plc (SVNS)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Solvonis Therapeutics plc betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Solvonis Therapeutics plc von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Lam Research Corp. R Lam Research Corp. R
Lam Research Corp. R
LAR0.DE
- -
US
Siemens AG Siemens AG
Siemens AG
SIE.DE
$13.14B -
DE
Schneider Electric S.E. Schneider Electric S.E.
Schneider Electric S.E.
SU.PA
- -
FR
Siemens Energy AG Siemens Energy AG
Siemens Energy AG
ENR.DE
- -
DE
Parker-Hannifin Corporation Parker-Hannifin Corporation
Parker-Hannifin Corporation
PH.US
$4.56B -
US